Clinical trial
Oblimersen in Treating Patients With Merkel Cell Carcinoma
NCT00079131 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00079131 |
|---|---|
| Title | Oblimersen in Treating Patients With Merkel Cell Carcinoma |
| Official title | A Phase II Study of G3139 (Genasense ™) in Patients With Merkel Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Neuroendocrine Carcinoma of the Skin, Stage I Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Neuroendocrine Carcinoma of the Skin |
| Intervention type | Biological, Other |
| Interventions | oblimersen sodium, pharmacological study, laboratory biomarker analysis |
| Enrollment | 37 |
| Start date | Jan 1, 2004 |
| Primary completion | Jan 1, 2007 |
| First posted | Mar 9, 2004 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: